aTYR PHARMA (ATYR) Share-based Compensation (2014 - 2026)

aTYR PHARMA (ATYR) has reported Share-based Compensation for 13 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 12.26% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $5.0 million (up 24.0% YoY), and the FY2025 full-year result was $5.0 million, up 67.18% from the prior year.
• Share-based Compensation slipped to $1.1 million in Q2 2026 per ATYR's latest filing, from $1.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.1 million in Q4 2022 and bottomed at $417000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $1.2 million across 5 years, with a median of $761000.0 in 2024.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 1626.09% in 2022, then slumped 91.24% in 2023.
• Over 5 years, Share-based Compensation stood at $7.1 million in 2022, then plunged by 91.24% to $626000.0 in 2023, then gained by 23.0% to $770000.0 in 2024, then soared by 56.75% to $1.2 million in 2025, then declined by 5.14% to $1.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $1.3 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.